In the first quarter of 2011, Merck Group total revenues increased 22% to EUR 2,564 million from EUR 2,099 million in the year-ago quarter, with the July 2010 acquisition of the Millipore Corporation in the United States continuing to have a positive effect. Acquisitions – mainly Millipore – and divestments accounted for 16 percentage points of the increase while positive currency effects and organic growth were responsible for 3.2 percentage points and 3.1 percentage points, respectively. In addition, as mentioned in the year-ago report, pharmaceutical sales in the first quarter of 2010 were about EUR 50 million higher than normal because wholesalers in the United States had received an extra 20 days supply of Rebif® and other products during March. This was a precautionary measure because Merck’s US subsidiary EMD Serono was converting its computer system in April 2010.
Royalty, license and commission income in the first quarter of 2011 increased 13% to EUR 86 million, mainly stemming from the Merck Serono division.
|
Components of growth by division – Q1 |
XLS | ||||
|
|
|
|
|
|
|
|
Change in total revenues |
Merck Serono |
Consumer Health Care |
Merck Millipore |
Performance Materials |
Merck Group |
|
Organic growth |
0.5 |
5.8 |
2.0 |
13.7 |
3.1 |
|
Currency effects |
2.4 |
2.6 |
3.7 |
6.4 |
3.2 |
|
Acquisitions/divestments |
–1.4 |
– |
160.5 |
–4.9 |
15.8 |
|
Total |
1.5 |
8.4 |
166.2 |
15.2 |
22.1 |